'Game-changing’ Alzheimer’s drug lecenemab rejected by EU
29 July 2024
“This conservative approach means that patients and doctors eager to explore a proven effective drug are now denied access," explains Professor Bart De Strooper (Ïã¸ÛÁùºÏ²Ê Queen Square Institute of Neurology).